Rosen Law Firm Encourages Nektar Therapeutics Investors to Secure Counsel Before Deadline

Investors who purchased Nektar securities between February 2025 and December 2025 may be eligible for compensation.

Mar. 23, 2026 at 6:01am

Got story updates? Submit your updates here. ›

Rosen Law Firm, a global investor rights law firm, is reminding purchasers of Nektar Therapeutics (NASDAQ: NKTR) securities between February 26, 2025 and December 15, 2025 of the important May 5, 2026 lead plaintiff deadline in a securities class action lawsuit. The lawsuit alleges that Nektar made false and/or misleading statements about the REZOLVE-AA trial, which had a significant negative impact on the trial's results and overall integrity.

Why it matters

This case highlights the importance for investors to be aware of potential securities fraud and to seek qualified legal counsel to protect their rights. The Rosen Law Firm is encouraging Nektar investors to join the class action lawsuit, which could potentially lead to compensation without any out-of-pocket fees or costs.

The details

According to the lawsuit, Nektar is accused of making false and/or misleading statements about the REZOLVE-AA trial, including that enrollment did not follow applicable instructions and protocol standards, which was likely to have a significant negative impact on the trial's results. The lawsuit claims that when the true details entered the market, investors suffered damages.

  • The class period is from February 26, 2025 to December 15, 2025, both dates inclusive.
  • The lead plaintiff deadline is May 5, 2026.

The players

Rosen Law Firm

A global investor rights law firm that is representing investors in the Nektar Therapeutics securities class action lawsuit.

Nektar Therapeutics

A biopharmaceutical company that is the subject of the securities class action lawsuit.

Got photos? Submit your photos here. ›

What they’re saying

“To join the Nektar class action, go to https://rosenlegal.com/submit-form/?case_id=55599 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action.”

— Phillip Kim, Esq.

What’s next

The judge will decide on May 5, 2026 whether to certify the class in the Nektar Therapeutics securities class action lawsuit.

The takeaway

This case underscores the importance for investors to be vigilant and seek qualified legal counsel when they suspect potential securities fraud. The Rosen Law Firm is encouraging affected Nektar Therapeutics investors to join the class action lawsuit before the upcoming lead plaintiff deadline.